The Petri Dish: Group eyes Biogen Alzheimer’s drug price, FDA rejects psych drug application

The FDA has elected not to accept a new drug application from Minerva Neurosciences Inc., sending shares plummeting. Read this, and more, in the latest biotech news roundup, The Petri Dish.